AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01567-06v1
51/9/3434    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gill, C. J.
Right arrow Articles by Hickey, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gill, C. J.
Right arrow Articles by Hickey, E. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2007, p. 3434-3436, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.01567-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

In Vivo Efficacy of a Novel Oxazolidinone Compound in Two Mouse Models of Infection{triangledown}

Charles J. Gill,* George K. Abruzzo, Amy M. Flattery, Andrew S. Misura, Ken Bartizal, and Emily J. Hickey

Department of Infectious Diseases, Merck Research Laboratories, Rahway, New Jersey 07065

Received 18 December 2006/ Returned for modification 17 January 2007/ Accepted 22 June 2007

A novel oxazolidinone, AM 7359, was evaluated in two mouse models of Staphylococcus aureus infection. AM 7359 and linezolid were equally efficacious in a methicillin-susceptible S. aureus organ burden model and a methicillin-resistant S. aureus localized infection model. However, AM 7359 was eightfold more efficacious than linezolid against a linezolid- and methicillin-resistant S. aureus strain in this localized (thigh) infection model.

* Corresponding author. Mailing address: R80Y-265, Merck & Co., Inc., P.O. Box 2000, Rahway, NJ 07065. Phone: (732) 594-6053. Fax: (732) 594-1298. E-mail: charles_gill{at}merck.com

{triangledown} Published ahead of print on 2 July 2007.

Antimicrobial Agents and Chemotherapy, September 2007, p. 3434-3436, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.01567-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.